Patents by Inventor Tilmann BUERCKSTUEMMER
Tilmann BUERCKSTUEMMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151392Abstract: An isolated mammalian host cell comprising a heterologous gene of interest (GOI) chromosomally integrated at a target site within an intergenic region between a pair of adjacent essential genes.Type: ApplicationFiled: July 28, 2022Publication date: May 18, 2023Inventors: Julian JUDE, Anatoly VASILYEV, Adam KREJCI, Tilmann BUERCKSTUEMMER, Anke LOREGGER, Lukas BADERTSCHER
-
Publication number: 20230015722Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.Type: ApplicationFiled: July 26, 2021Publication date: January 19, 2023Inventors: Thomas HENLEY, Mavis AGBANDJE-MCKENNA, Tilmann BUERCKSTUEMMER, Lydia VINEY, Modassir CHOUDHRY
-
Publication number: 20230018860Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.Type: ApplicationFiled: July 26, 2021Publication date: January 19, 2023Inventors: Thomas HENLEY, Mavis AGBANDJE-MCKENNA, Tilmann BUERCKSTUEMMER, Lydia VINEY, Modassir CHOUDHRY
-
Patent number: 11396664Abstract: The invention relates to a system and method for introducing DNA into cells. In particular, the invention relates to a method for introducing single or multiple copies of a DNA sequence or gene of interest into a cell comprising providing: a) a “copy and paste” transposase; and b) a construct comprising a DNA sequence or gene of interest flanked by a “copy and paste” transposon terminal sequence, such as an LTS or RTS. A novel “copy and paste” transposon of the Helitron family is described along with systems for using the corresponding transposase in methods for introducing DNA into cells, for example, to generate cell lines for use in protein production, cell and gene therapy or as reference standards.Type: GrantFiled: February 10, 2017Date of Patent: July 26, 2022Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, GENETIC INFORMATION RESEARCH INSTITUTEInventors: Tilmann Buerckstuemmer, Vladimir Vyacheslavovich Kapitonov, Ivana Grabundzija, Zoltan Ivics
-
Publication number: 20220089659Abstract: Constructs comprising Argonautes and neighboring genes are disclosed for use in gene editing. Disclosed are also compositions and methods utilizing these Argonautes and neighboring genes. Also disclosed are the methods of making and using the Argonautes and neighboring genes in treating various diseases, conditions, and cancer.Type: ApplicationFiled: September 1, 2021Publication date: March 24, 2022Applicants: The Board of Trustees of the Leland Stanford Junior University, Intima Bioscience, Inc.Inventors: Lei S. Qi, Modassir Choudhry, Xueqiu Lin, Trevor N. Collingwood, Thomas Henley, Benjamin Klapholz, Tilmann Buerckstuemmer, Sejla Salic
-
Publication number: 20220064668Abstract: Adeno-associated virus has numerous advantages for its use in gene therapy. The present disclosures provide genetically modified adeno-associated viral vectors, and the methods of making the genetically modified adeno-associated viral vectors and compositions in treating cancer, other conditions, diseases, and disorders.Type: ApplicationFiled: July 1, 2021Publication date: March 3, 2022Inventors: Modassir CHOUDHRY, Mavis AGBANDJE-MCKENNA, Tilmann BUERCKSTUEMMER, Thomas HENLEY, Lydia VINEY
-
Patent number: 11098325Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.Type: GrantFiled: December 18, 2019Date of Patent: August 24, 2021Assignee: INTIMA BIOSCIENCE, INC.Inventors: Thomas Henley, Mavis Agbandje-McKenna, Tilmann Buerckstuemmer, Lydia Viney, Modassir Choudhry
-
Publication number: 20200354743Abstract: Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.Type: ApplicationFiled: December 18, 2019Publication date: November 12, 2020Inventors: THOMAS HENLEY, MAVIS AGBANDJE-MCKENNA, TILMANN BUERCKSTUEMMER, LYDIA VINEY, MODASSIR CHOUDHRY
-
Patent number: 10557151Abstract: The invention provides for a method of producing a mutant somatic human cell line of cells comprising a genomic mutation of interest (MOI) at a predefined genomic site of interest (GOI) in close proximity to a genomic target site, which comprises: a) providing a guide RNA (gRNA) comprising a tracrRNA in conjunction with crRNA including an oligonucleotide sequence that hybridizes with the target site; b) providing an RNA-guided endonuclease which catalyzes the DNA break at the target site upon hybridizing with the gRNA; c) introducing the gRNA into the cells in the presence of the endonuclease to obtain a repertoire of cells comprising a variety of genomic mutations at the target site; d) selecting a cell from said repertoire which comprises a MOI; wherein the cell is haploid for the genomic locus of the target site; and e) expanding the cell to obtain the mutant cell line.Type: GrantFiled: November 28, 2014Date of Patent: February 11, 2020Assignee: Horizon Discovery LimitedInventor: Tilmann Buerckstuemmer
-
Publication number: 20200032294Abstract: The invention provides for a somatic fully haploid, karyotypically stable human cell line, e.g. obtainable by targeted deletion of one or more disomic chromosomal regions of a somatic near-haploid human parental cell, a method of producing the same, as well as the use of the cell line for producing isogenic cell variants, comprising genomic mutations at different genomic target sites, and a library of such cell variants.Type: ApplicationFiled: September 11, 2019Publication date: January 30, 2020Applicant: HORIZON DISCOVERY LIMITEDInventor: Tilmann BUERCKSTUEMMER
-
Publication number: 20190323037Abstract: The invention relates to a system and method for introducing DNA into cells. In particular, the invention relates to a method for introducing single or multiple copies of a DNA sequence or gene of interest into a cell comprising providing: a) a “copy and paste” transposase; and b) a construct comprising a DNA sequence or gene of interest flanked by a “copy and paste” transposon terminal sequence, such as an LTS or RTS. A novel “copy and paste” transposon of the Helitron family is described along with systems for using the corresponding transposase in methods for introducing DNA into cells, for example, to generate cell lines for use in protein production, cell and gene therapy or as reference standards.Type: ApplicationFiled: February 10, 2017Publication date: October 24, 2019Inventors: Tilmann BUERCKSTUEMMER, Vladimir Vyacheslavovich KAPITONOV, Ivana GRABUNDZIJA, Zoltan IVICS
-
Patent number: 10450586Abstract: The invention provides for a somatic fully haploid, karyotypically stable human cell line, e.g. obtainable by targeted deletion of one or more disomic chromosomal regions of a somatic near-haploid human parental cell, a method of producing the same, as well as the use of the cell line for producing isogenic cell variants, comprising genomic mutations at different genomic target sites, and a library of such cell variants.Type: GrantFiled: November 28, 2014Date of Patent: October 22, 2019Assignee: Horizon Discovery LimitedInventor: Tilmann Buerckstuemmer
-
Publication number: 20170009256Abstract: The invention provides for a method of producing a mutant somatic human cell line of cells comprising a genomic mutation of interest (MOI) at a predefined genomic site of interest (GOI) in close proximity to a genomic target site, which comprises: a) providing a guide RNA (gRNA) comprising a tracrRNA in conjunction with crRNA including an oligonucleotide sequence that hybridizes with the target site; b) providing an RNA-guided endonuclease which catalyzes the DNA break at the target site upon hybridizing with the gRNA; c) introducing the gRNA into the cells in the presence of the endonuclease to obtain a repertoire of cells comprising a variety of genomic mutations at the target site; d) selecting a cell from said repertoire which comprises a MOI; wherein the cell is haploid for the genomic locus of the target site; and e) expanding the cell to obtain the mutant cell line.Type: ApplicationFiled: November 28, 2014Publication date: January 12, 2017Inventor: Tilmann BUERCKSTUEMMER
-
Publication number: 20170002380Abstract: The invention provides for a somatic fully haploid, karyotypically stable human cell line, e.g. obtainable by targeted deletion of one or more disomic chromosomal regions of a somatic near-haploid human parental cell, a method of producing the same, as well as the use of the cell line for producing isogenic cell variants, comprising genomic mutations at different genomic target sites, and a library of such cell variants.Type: ApplicationFiled: November 28, 2014Publication date: January 5, 2017Inventor: Tilmann BUERCKSTUEMMER